Walleye Capital LLC Viking Therapeutics, Inc. Put Options Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $1.72 Million - $2.43 Million	34,500 Added 410.71%	42,900 $2.72 Million
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $369,642 - $625,560	7,800 Added 1300.0%	8,400 $445,000
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $125,279 - $680,400	-7,200 Reduced 92.31%	600 $49,000
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $72,072 - $153,192	7,800 New	7,800 $145,000
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $26,712 - $44,622	1,800 Added 69.23%	4,400 $71,000
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $21,008 - $45,057	2,600 New	2,600 $43,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.